Teclistamab in Relapsed or Refractory Multiple Myeloma

• Published in: The New England journal of medicine Vol. 387; no. 6; pp. 495 - 505
• Main Authors: Moreau, Philippe, Garfall, Alfred L., van de Donk, Niels W.C.J., Nahi, Hareth, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun X.W., Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D., Kobos, Rachel, Krishnan, Amrita, Usmani, Saad Z.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 11.08.2022
• Subjects: Antibodies; Antibodies, Bispecific - administration & dosage; Antibodies, Bispecific - adverse effects; Antibodies, Bispecific - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B-Cell Maturation Antigen - antagonists & inhibitors; Bispecific antibodies; Body weight; CD3 antigen; CD3 Complex - antagonists & inhibitors; CD38 antigen; Cell surface; Cytokines; Drug dosages; Hematology; Humans; Immunomodulation; Immunotherapy; Injections, Subcutaneous; Leukemia; Lymphocytes B; Lymphocytes T; Lymphoma; Medicin och hälsovetenskap; Minimal residual disease; Monoclonal antibodies; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - immunology; Multiple Myeloma - pathology; Neoplasm Recurrence, Local - drug therapy; Neurotoxicity; Neutropenia; Oncology; Patient safety; Pharmacokinetics; Proteasome inhibitors; Recurrence; Response rates; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Targeted cancer therapy; Thrombocytopenia; Treatments in Oncology; Working groups
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2203478

In this phase 1–2 study involving patients with relapsed or refractory myeloma, a bispecific antibody (teclistamab) that mediates T-cell activation and subsequent lysis of myeloma cells expressing B-cell maturation antigen induced responses in 63% of the patients, including a complete response in nearly 40%.